EUSA Pharma

London-based pharmaceutical company EUSA Pharma markets new drugs to combat serious diseases.

We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.

Strategy and Growth

Buy-Side Advisory

Healthcare and Life Sciences

Lesezeit 3 minutes

Zentrale Ergebnisse

Purchase of global marketing rights to dinutuximab beta

by EUSA Pharma, quickly managed to obtain European approval.

Development of dinutuximab beta

for the treatment of neuroblastoma, the second most common solid tumor in children, by the Austrian biotech company Apeiron.

Approval of the drug

in the pipeline in the USA (as of September 2017).

Scroll down

The challenge

We were informed by the equity firm Essex Woodlands, which had invested in EUSA Pharma, and by the latter company itself that it was on the look-out for innovative drugs as part of its growth strategy.
EUSA Pharma was willing to acquire the rights to drugs for which approval had yet to be granted. Seizing the initiative, our pharmaceutical team went in search of a suitable drug.

Dark blue Background with multiple viruses in the front.

The solution

Thanks to its network of medics and pharmaceutical experts, the team was able to identify Apeiron´s immunotherapy for the treatment of brain tumors as a suitable target for purchase. Apeiron itself lacked the resources for marketing.

The team of consultants arranged a meeting and EUSA Pharma lost no time in taking action: European approval was applied for shortly after the completion of due diligence and conclusion of the purchase contract, and granted soon afterwards.